Teva Pharmaceutical Industries will release its Q2 2025 financial results on July 30, 2025, with a conference call following.
Quiver AI Summary
Teva Pharmaceutical Industries Ltd. announced that it will release its second quarter 2025 financial results on July 30, 2025, at 7:00 a.m. ET, followed by a conference call and live webcast at 8:00 a.m. ET. Participants are required to register in advance to obtain access information. A replay of the webcast will be available on Teva's website within 24 hours after the call. Teva, a leader in global biopharmaceuticals with over 120 years of commitment to health, continues to innovate and address patient needs across various markets. The company also provided caution regarding forward-looking statements that may be included in the release and the call, which are subject to risks and uncertainties. For more information, media and investor inquiries can be directed to the respective contacts provided.
Potential Positives
- Teva Pharmaceutical Industries Ltd. is set to release its second quarter 2025 financial results, indicating transparency and accountability to investors and stakeholders.
- The conference call and live webcast provide an opportunity for real-time engagement, allowing investors to ask questions and receive immediate responses.
- The company emphasizes its long-standing commitment to health innovation and its broad operational capabilities across 57 markets, showcasing its stability and global presence.
Potential Negatives
- Teva's upcoming financial results announcement may raise concerns among investors regarding the company's ongoing financial performance, especially given its significant indebtedness as highlighted in the release.
- The mention of risks related to compliance, regulatory, and litigation matters may indicate potential legal challenges that could impact the company's operations and financial stability.
- The emphasis on the "Pivot to Growth" strategy suggests that the company may be facing challenges in its current market position and is attempting to shift its business approach, which may not reassure investors about its stability.
FAQ
When will Teva release its Q2 2025 financial results?
Teva will issue its Q2 2025 financial results on July 30, 2025, at 7:00 a.m. ET.
How can I participate in the Teva conference call?
To participate, please register in advance to obtain a local or toll-free phone number and your personal pin.
Where can I find the live webcast of the conference call?
The live webcast will be available on Teva's website at https://ir.tevapharm.com/Events-and-Presentations.
Will there be a replay of the conference call?
Yes, a replay of the webcast will be available within 24 hours on Teva's website.
What is Teva's commitment to healthcare?
Teva is dedicated to addressing patients’ needs by developing innovative medicines and promoting generics and biologics.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$TEVA Insider Trading Activity
$TEVA insiders have traded $TEVA stock on the open market 19 times in the past 6 months. Of those trades, 0 have been purchases and 19 have been sales.
Here’s a breakdown of recent trading of $TEVA stock by insiders over the last 6 months:
- MARK SABAG (See "Remarks") sold 337,915 shares for an estimated $6,097,304
- RICHARD DANIELL (Exec. VP, European Commercial) has made 0 purchases and 10 sales selling 273,583 shares for an estimated $4,345,473.
- ELIYAHU SHARON KALIF (EVP, Chief Financial Officer) sold 55,775 shares for an estimated $952,464
- ERIC A HUGHES (See "Remarks") has made 0 purchases and 4 sales selling 48,151 shares for an estimated $767,057.
- RICHARD D FRANCIS (President and CEO) has made 0 purchases and 2 sales selling 23,773 shares for an estimated $375,533.
- MATTHEW SHIELDS (EVP, Global Operations) sold 6,206 shares for an estimated $105,627
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$TEVA Hedge Fund Activity
We have seen 258 institutional investors add shares of $TEVA stock to their portfolio, and 302 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- HAREL INSURANCE INVESTMENTS & FINANCIAL SERVICES LTD. added 22,044,407 shares (+197885.2%) to their portfolio in Q1 2025, for an estimated $338,822,535
- RUBRIC CAPITAL MANAGEMENT LP added 8,550,000 shares (+50.3%) to their portfolio in Q1 2025, for an estimated $131,413,500
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP removed 6,990,407 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $107,442,555
- GOLDMAN SACHS GROUP INC added 6,859,718 shares (+195.1%) to their portfolio in Q1 2025, for an estimated $105,433,865
- GLENVIEW CAPITAL MANAGEMENT, LLC added 6,322,317 shares (+74.8%) to their portfolio in Q1 2025, for an estimated $97,174,012
- PHOENIX FINANCIAL LTD. added 6,252,030 shares (+29.5%) to their portfolio in Q1 2025, for an estimated $96,093,701
- DUQUESNE FAMILY OFFICE LLC added 5,882,350 shares (+65.4%) to their portfolio in Q1 2025, for an estimated $90,411,719
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
TEL AVIV, Israel, June 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2025 financial results on Wednesday, July 30, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.
In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin.
A live webcast of the call will be available on Teva's website at: https://ir.tevapharm.com/Events-and-Presentations .
Following the conclusion of the call, a replay of the webcast will be available within 24 hours on Teva's website.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a different kind of global biopharmaceutical leader, one that operates across the full spectrum of innovation to reliably deliver medicines to patients worldwide. For over 120 years, Teva’s commitment to bettering health has never wavered. Today, the company’s global network of capabilities enables its 37,000 employees across 57 markets to advance health by developing medicines for the future while championing the production of generics and biologics. We are dedicated to addressing patients’ needs, now and in the future. Moving forward together with science that treats, inspired by the people we serve. To learn more about how Teva is all in for better health, visit
www.tevapharm.com
.
Cautionary Note Regarding Forward-Looking Statements
This press release and the conference call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace including our ability to successfully execute our Pivot to Growth strategy; our significant indebtedness; our business and operations in general; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in this press release and in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the sections captioned "Risk Factors”. Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
Teva Media Inquiries
[email protected]
Teva Investor Relations Inquires
[email protected]
